Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02170688
Other study ID # Pro00010850
Secondary ID
Status Completed
Phase Phase 4
First received June 20, 2014
Last updated December 17, 2014
Start date February 2004
Est. completion date July 2014

Study information

Verified date December 2014
Source Duke University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

There are several different methods that can be used to determine the dose of iodinated contrast material for a CT scan. These include a standard fixed dose, a dose based on total body weight, a dose based on body mass index, a dose based on lean body weight, and a dose based on estimated lean body weight. The fixed dose method uses a predetermined amount of contrast material for all patients having a CT scan of the abdomen regardless of size. This is the standard procedure currently used at Duke. The other methods use the patient's weight, either the total body weight or lean body weight, to determine the amount of contrast necessary for the CT exam. For this study, the investigators will use the fixed dose, total body weight, the lean body weight, and estimated lean body weight methods. The purpose of this study is to evaluate these five methods of determining the IV contrast volume and which may be best for abdominal CT scanning.


Recruitment information / eligibility

Status Completed
Enrollment 139
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- male or non-lactating, non-pregnant females

- 18 years or older who are able to give written informed consent

Exclusion Criteria:

- a chronic underlying liver disease such as cirrhosis, fatty infiltration of the liver or glycogen storage diseases

- patients with a prolonged cardiac transit time such as those with a congested heart failure, a history of prior cardiac valve replacement, or restrictive/constrictive pericarditis

- patients having undergone any other radiological procedure utilizing iodinated contrast with the 24 hours prior to the CT exam

- patients above a certain total body weight (440 lbs.) due to limitation of the scales themselves (determined by manufacturer)

- any subjects with a history of hypersensitivity to iodine-containing compounds or renal insufficiency (serum creatinine >1.8)

- subjects with implanted electronic devices (pacemakers, defibrillators, insulin pumps, etc.)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)


Related Conditions & MeSH terms


Intervention

Drug:
Isovue 370
All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
Other:
Weight calculation


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in Enhancement of the Liver and Blood Vessels Over Time, Measured in Hounsfield Units (HU) Operator-defined regions-of-interest (ROI) will be obtained from liver parenchyma, the portal vein and the abdominal aorta prior to contrast administration and on each slice through the liver post-contrast. Sum of all three areas reported as Summed measurement. baseline, post-dose imaging (approximately 1hr) No
Secondary Difference in Volume of Contrast Used, Measured in Milliliters baseline, post-dose imaging (approximately 1hr) No